Participants should not have received any other investigational agents nor have participated in an investigational trial within the past weeks Patients must not have received radiation therapy, non-cytotoxic agents or investigational agents or systemic corticosteroids within days prior to registration Subject has received other investigational therapy within the last days. Patients may not be receiving or have received any other investigational agents during/or within month prior Patients may not have received any other investigational agents within the last days at the time of treatment start Patients who are receiving any other investigational or chemotherapeutic agents will be excluded; please contact the study principal investigator (PI) if a patient has received an investigational or chemotherapeutic agent in the past Patients may not be receiving any other investigational agents; (i.e. -day washout period from prior investigational drug is required) Patients who are receiving any other investigational agents, or have received an investigational agent within the past days Patients may not be receiving any other investigational agents, or have received investigational agents within weeks of beginning treatment Patients may not be receiving (or received prior to enrollment) any other investigational agents for metastatic disease. Patients who are receiving any other investigational agents. A minimum washout period of days is required prior to the initiation of on study treatment. Patients who have received any other investigational agents within the past days prior to cycle day Receiving any other investigational agents, or has received an investigational agent within the last days Major surgery (including breast surgery) within < days of starting treatment or received chemotherapy, investigational agents, or other cancer therapy < days prior to the initiation of investigational products (except adjuvant endocrine therapy) Patients receiving any other investigational agents; any prior investigational agents must be stopped at least days ( week washout) prior to registration Patients should not have received any other investigational agents within the past weeks Treatment with other investigational agents within days of day Patients receiving any other investigational agents or whom have received recent treatment for colorectal cancer (radiation within the previous two weeks, chemotherapy or investigational therapy within the previous four weeks) Patients who are receiving any other investigational agents, or have received an investigational agent within the past days Patients receiving any other investigational chemotherapeutic agents within days prior to the first dose of trial treatment JUST PRIOR TO FIRST VACCINATION (WITHIN DAYS): patients may not be receiving any other investigational agents Subjects must not have received any investigational agents within days of study entry Subjects may have received any other investigational agents or chemotherapy as long as they are eligible for SABR and surgery Patients may not be receiving any other investigational agents nor have participated in an investigational trial within the past weeks Past history of other investigational agents Patients must not have received other investigational agents within days of initiation of the conditioning regimen Patients must not have received any investigational agents within days of study entry Must not be receiving any other investigational agents within days of first dose of azacitidine (day ) Simultaneous primary invasive cancers or patients currently receiving any other investigational agents at time of study enrollment. Patients may have received investigational agents in the past. No washout time period is required. Subject has received other investigational agents or devices within days prior to first dose of study treatment. Participants may not have received any other investigational agents in the previous months Patients who have received any other investigational agents within the preceding weeks Patients who are receiving any other investigational agents require a week washout period; patients who have received cellular or gene therapy at any time are not eligible Treatment with other investigational agents within days of day Patients are not eligible who have received systemic chemotherapy or investigational agents =< days prior to registration Subjects must not have received any investigational agents within days of study entry Patients may not be receiving or have received any other investigational agents during or within month prior to treatment with NFV Patients who have received any other investigational agents within the last weeks Patients must NOT be receiving any other investigational agents concurrently and must not have received any other investigational agents =< weeks prior to registration PHASE II: Patients must NOT be receiving any other investigational agents concurrently and must not have received any other investigational agents =< weeks prior to randomization Major surgery within < days of starting treatment or received chemotherapy, investigational agents, or other cancer therapy, except hormonal therapy (eg, tamoxifen, aromatase inhibitors), < days prior to the initiation of investigational products Received other investigational agents within days prior to the start of the conditioning regimen Patients may not have received any other investigational agents within weeks of study entry Subjects who are receiving or have received any other investigational agents within days prior to day of treatment in this study Received no other investigational therapy within the past days Participants may not be receiving any other investigational agents nor have participated in an investigational trial within the past weeks Patients receiving any other investigational agents within days prior to the first dose of trial treatment Participants should not have received any other investigational agents nor have participated in an investigational trial within the past weeks Subjects who have received investigational agents within days of the first day of study drug. Patients who are receiving any other investigational agents or who have received pomalidomide in the past Subjects who are receiving any other investigational agents or who have received an investigational agent within days prior to enrollment (does not apply to participation in survival follow up), or who have previous exposure to vandetanib Patients may not be receiving or have received any other investigational agents during/or within month prior to treatment with oregovomab or nelfinavir No patients receiving other investigational therapy for the past days before dosing. Patient must not have received any other investigational agents within days prior to study enrollment Patients may not be receiving any other investigational agents; any prior investigational products must be stopped at least days (-week washout) prior to registration Treatment with other investigational agents within days of day Patients may not be receiving any other investigational agents nor have received any investigational drug days prior to enrollment Patients must not have received any other investigational agents within days prior to vaccination. Patient must not have received treatment with other investigational agents within the last weeks Subjects who have received investigational agents must wait at least weeks Received any other investigational therapy within days of Day ; or Patients who are receiving any other investigational agents; if the patient received a previous investigational or other agent or treatment, a washout period of weeks is required Subjects who have received any other investigational agents within days of first lithium dose Has the subject received any investigational treatment within the past days? Patients may not be receiving any other investigational agents; a minimum week washout period is required Patients who are receiving or have received any other investigational agents within days of study day , or who have previously received MK- at any time Subjects who are receiving any other investigational agents or have received another investigational drug in the last days Patients must not have received any investigational agents within days prior to commencing study treatment Participants may not have received any other investigational agents in the previous months Patients may not be receiving any other investigational agents; any prior investigational therapeutic products must be stopped at least days ( week washout) prior to treatment start Have received other investigational agents within the past months (preceding the time of registration) Patients who are receiving any other investigational agents (in the past days) or herbal medication (within day) Patients who are receiving any other investigational agents (in the past days) or herbal medications (within day) Patients who are receiving any other investigational agents (in the past days) or herbal medications (within days)